Moreover, in mixed lineage leukemia (MLL)-AF9-driven mouse AML and in human AML cells, resistance to BET inhibitors was due to increased activity of β-catenin and restoration of c-myc expression [123]. This evidence concerns the gene MYC and acute myeloid leukemia.